SCHEMBL6174216

SCHEMBL6174216

CC(C)(C)OC(=O)N1CCCC[C@@H]1CCOS(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.46
CHEK2 O96017 1/20 0.42
PDE8B O95263 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
APP P05067 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
DRD2 P14416 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
SLC6A2 P23975 1/20 0.40
HRH2 P25021 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR7 P34969 1/20 0.40
DRD3 P35462 1/20 0.40
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3126719 1.00 ATM (0.46) ATMCHEK2PDE8BHSD17B10TRPV1
SCHEMBL2915181 1.00 ATM (0.46) ATMCHEK2PDE8BHSD17B10TRPV1
SCHEMBL16538591 0.97 ATM (0.45) ATMCHEK2PDE8BHSD17B10APP
SCHEMBL3120002 0.97 ATM (0.45) ATMCHEK2PDE8BHSD17B10APP
SCHEMBL3130359 0.97 ATM (0.45) ATMCHEK2PDE8BHSD17B10APP
SCHEMBL23988660 0.91 ATM (0.43) ATMCHEK2HSD17B10APPHTR1A
SCHEMBL1193279 0.88 PDE8B (0.43) ATMPDE8BHSD17B10APPHTR1A
SCHEMBL7106146 0.88 PDE8B (0.43) ATMPDE8BHSD17B10APPHTR1A
SCHEMBL428028 0.87 HSD17B10 (0.44) ATMPDE8BHSD17B10APPHTR1A
SCHEMBL426040 0.87 HSD17B10 (0.44) ATMPDE8BHSD17B10APPHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140904-B1 FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORP (US) 2005-04-20 EP disclosed
US-6800636-B2 FOR THERAPY OF CANCER SCHERING CORPORATION 2004-10-05 US disclosed
US-20030040520-A1 Farnesyl protein transferase inhibitors GUZI TIMOTHY (US) 2003-02-27 US disclosed
US-6362188-B1 ANTICANCER AGENTS SCHERING CORPORATION 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040520-A1 Farnesyl protein transferase inhibitors FNTA, FNTB, CETP ATM 3483/4885CHEK2 3290/4885PDE8B 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.